Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
ABOS Chart
Acumen Pharmaceuticals, Inc. Dividends
Acumen Pharmaceuticals, Inc. Earnings
| 12 May 2025 (41 Days) Date | | - Cons. EPS | - EPS |
| 24 Mar 2025 Date | | - Cons. EPS | - EPS |
| 13 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 May 2025 (41 Days) Date | | - Cons. EPS | - EPS |
| 24 Mar 2025 Date | | - Cons. EPS | - EPS |
| 13 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
Acumen Pharmaceuticals, Inc. (ABOS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Acumen Pharmaceuticals, Inc. ever had a stock split?
Acumen Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Daniel J. O'Connell M.B.A. CEO | NASDAQ (NGS) Exchange | US00509G2093 ISIN |
| United States Country | 51 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for Alzheimer's disease. With a focus on innovation and a pioneering approach to treatment, this company is at the forefront of advancing research and therapy options for one of the most challenging neurodegenerative diseases faced globally. Founded in 1996 and based in Charlottesville, Virginia, Acumen Pharmaceuticals has established itself as a leader in the field, aiming to significantly impact the lives of patients suffering from Alzheimer's disease through groundbreaking treatment solutions.
Products and Services
- Sabirnetug (ACU193)
- Manufacturing and Commercialization Agreement with Lonza Sales AG
- Collaboration and License Agreement with Halozyme, Inc.
A flagship product, sabirnetug (ACU193), represents the core of Acumen Pharmaceuticals’ targeted immunotherapy offerings. It is a recombinant humanized immunoglobulin gamma 2 designed specifically to target soluble amyloid-beta oligomers. Soluble amyloid-beta oligomers are believed to play a critical role in the development and progression of Alzheimer's disease, making ACU193 a significant advancement in targeted therapy. Having completed Phase I clinical trials, sabirnetug is at the forefront of Acumen’s mission to fight Alzheimer's disease.
Acumen Pharmaceuticals has entered into a license agreement with Lonza Sales AG, which encompasses the manufacture and commercialization of sabirnetug. This partnership highlights the company's strategic steps toward ensuring the availability and scalability of this promising therapeutic candidate, emphasizing its commitment to advancing care for Alzheimer's disease patients.
The collaboration with Halozyme, Inc. focuses on the development of a subcutaneous formulation of sabirnetug. This innovative approach aims to improve the delivery and efficacy of the treatment, making it more accessible and potentially more effective for patients. The partnership with Halozyme, Inc. underlines Acumen’s dedication to enhancing Alzheimer's disease treatments through scientific and strategic collaborations.
Contact Information
